# Xingjuan (Jane) Chao

> Xingjuan (Jane) Chao is Ceribell’s co-founder, president, CEO, and a director. Trained in chemistry at Peking University and biophysics at Cornell, she also studied filmmaking before a business career at McKinsey, Novartis, and Genentech. She led Ceribell through its October 2024 Nasdaq listing and was included in Inc.’s 2025 Female Founders 500.

- **Role:** Co-founder, President, Chief Executive Officer, and Director at Ceribell
- **Organizations:** Ceribell, McKinsey & Company, Novartis, Genentech, Magnus Medical
- **Education:** B.S. in chemistry, Peking University, Ph.D. in biophysics, Cornell University, Postdoctoral fellowship, University of California, San Francisco, One year of study in cinematography and directing; degree not stated, Beijing Film Academy
- **Known for:** Co-founded Ceribell in 2014 and led it from an early company through its public listing., Led Ceribell through its October 2024 IPO, which raised approximately $207.3 million in gross proceeds including the underwriters’ option., Named to Inc.’s 2025 Female Founders 500.

## Career timeline

- **2005** — Earned her Ph.D. in biophysics at Cornell University.
- **2007-2013** — Management consultant at McKinsey & Company, July 2007 to January 2013.
- **2013-2014** — Senior Strategy Manager at Novartis, January 2013 to June 2014.
- **2014-2015** — Principal Manager of Portfolio Management Strategy at Genentech, June 2014 to August 2015.
- **2014** — Co-founded Ceribell with Josef Parvizi and Chris Chafe.
- **2015** — Joined Ceribell full-time as CEO; the 2026 proxy dates her CEO appointment to October 2015 and board membership to August 2015.
- **2016** — Became Ceribell president in July.
- **2021-2025** — Served on the board of Magnus Medical from November 2021 to February 2025.
- **2024** — Led Ceribell through its October Nasdaq listing; IPO closed with approximately $207.3 million in gross proceeds.
- **2025** — Included in Inc.’s Female Founders 500.
- **2026** — Ceribell’s current leadership biography records a return to the Magnus Medical board in June.

## Achievements

- Co-founded Ceribell in 2014 and led it from an early company through its public listing.
- Led Ceribell through its October 2024 IPO, which raised approximately $207.3 million in gross proceeds including the underwriters’ option.
- Named to Inc.’s 2025 Female Founders 500.
- Earned a Ph.D. in biophysics from Cornell University.

## Latest updates

- **2026-10** — Ceribell announced on October 20 that its third-quarter results would be reported November 3, 2026; this was still upcoming as of research on October 25.
- **2026-08** — Ceribell reported second-quarter revenue of $28.1 million and a net loss of $19.3 million on August 10; Chao remained co-founder and CEO.
- **2026-06** — Ceribell’s current leadership biography states Chao rejoined the Magnus Medical board in June 2026.

## Links

- Website: https://ceribell.com/
- LinkedIn: https://www.linkedin.com/in/xingjuan-jane-chao-1311333

---

Profile page: https://yespress.io/jane-chao
Published by YesPress — https://yespress.io
Last updated: 2026-10-25